Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Май 17, 2023

Inflammation contributes to many chronic conditions. It is often associated with circulating pro-inflammatory cytokines and immune cells. GLP-1 levels correlate disease severity. They are elevated can serve as markers of inflammation. Previous studies have shown that oxytocin, hCG, ghrelin, alpha-MSH ACTH receptor-mediated anti-inflammatory properties rescue cells from damage death. These peptides been studied well in the past century. In contrast, its recognized only recently. has proven be a useful adjuvant therapy type-2 diabetes mellitus, metabolic syndrome, hyperglycemia. also lowers HbA1C protects cardiovascular nervous systems by reducing inflammation apoptosis. this review we explored link between GLP-1, inflammation, sepsis.

Язык: Английский

---

Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications

Therapeutic Advances in Endocrinology and Metabolism, Год журнала: 2024, Номер 15

Опубликована: Янв. 1, 2024

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have emerged as promising therapeutic agents with potent anti-inflammatory properties and diverse clinical implications. This in-depth review article explores the mechanisms behind actions of GLP-1RAs assesses their prospective applicability in a wide range disease scenarios. The current establishes significance comprehending role identifies pertinent research gaps. A concise overview inflammation its consequences underscores critical need for effective interventions. Subsequently, elucidates intricate through which modulate immune cell signaling regulate nuclear factor-kappa B (NF-κB) pathway. Detailed discussions encompass impact on inflammatory responses, cytokine production, attenuation oxidative stress. exposition is substantiated by collection examples an extensive array references from both preclinical investigations. historical trajectory GLP-1RA drugs, including exenatide, lixisenatide, liraglutide, semaglutide, traced to delineate development agents. Moreover, emphasizes potential specific contexts like type 2 diabetes, neurodegenerative disorder, bowel (IBD), shedding light effects rigorous examination studies. also provides outlook future perspectives GLP-1RAs, encompassing domains diseases, IBD. In conclusion, exhibit substantial effects, rendering them broad They are very useful variety diseases because they immunological block NF-κB activation, decrease production pro-inflammatory cytokines. Ongoing endeavors aim optimize use, patient-specific treatment paradigms, explore novel applications. represent significant breakthrough therapy, offering options, improved patient outcomes.

Язык: Английский

---

Metabolic memory: mechanisms and diseases

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Фев. 28, 2024

Metabolic diseases and their complications impose health economic burdens worldwide. Evidence from past experimental studies clinical trials suggests our body may have the ability to remember metabolic environment, such as hyperglycemia or hyperlipidemia, thus leading chronic inflammatory disorders other even after elimination of these environments. The long-term effects that aberrant metabolism on been summarized memory are found assume a crucial role in states disease. Multiple molecular mechanisms collectively participate management, resulting different cellular alterations well tissue organ dysfunctions, culminating disease progression affecting offspring. elucidation expansion concept provides more comprehensive insight into pathogenic underlying promises be new target detection management. Here, we retrace history relevant research summarize its salient characteristics. We provide detailed discussion by which involved development at molecular, cellular, levels, with emphasis impact epigenetic modulations. Finally, present some pivotal findings arguing favor targeting develop therapeutic strategies for latest reflections consequences implications human diseases.

Язык: Английский

---

Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases

Tissue Barriers, Год журнала: 2023, Номер 12(4)

Опубликована: Дек. 14, 2023

Background A number of peptide incretin receptor agonists (IRAs) show promise as therapeutics for Alzheimer's disease (AD) and Parkinson's (PD). Transport across the blood–brain barrier (BBB) is one way IRAs to act directly within brain. To determine which are high priority candidates treating these disorders, we have studied their brain uptake pharmacokinetics.

Язык: Английский

---

Type 2 Diabetes and Alzheimer’s Disease: The Emerging Role of Cellular Lipotoxicity

Biomolecules, Год журнала: 2023, Номер 13(1), С. 183 - 183

Опубликована: Янв. 16, 2023

Type 2 diabetes (T2D) and Alzheimer’s diseases (AD) represent major health issues that have reached alarming levels in the last decades. Although growing evidence demonstrates AD is a significant comorbidity of T2D, there ~1.4–2-fold increase risk developing among T2D patients, involvement possible common triggers pathogenesis these two remains largely unknown. Of note, recent mechanistic insights suggest lipotoxicity could missing ring pathogenetic mechanisms linking to AD. Indeed, obesity, which represents main cause lipotoxicity, has been recognized as factor for both pathological conditions. Lipotoxicity can lead inflammation, insulin resistance, oxidative stress, ceramide amyloid accumulation, endoplasmic reticulum ferroptosis, autophagy, are shared biological events In current review, we try provide critical comprehensive view molecular pathways activated by AD, attempting summarize how drive future research open way new therapeutic perspectives.

Язык: Английский

---

Unlocking longevity with GLP-1: A key to turn back the clock?

Maturitas, Год журнала: 2024, Номер 186, С. 108028 - 108028

Опубликована: Май 21, 2024

Язык: Английский

---

Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules

European Journal of Medicinal Chemistry, Год журнала: 2022, Номер 240, С. 114578 - 114578

Опубликована: Июль 9, 2022

Язык: Английский

---

Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—a choice determined by metabolic phenotype

Aging Clinical and Experimental Research, Год журнала: 2022, Номер 34(9), С. 1949 - 1967

Опубликована: Июнь 20, 2022

Abstract Frailty is a newly emerging complication of diabetes in older people and increasingly recognised national international clinical guidelines. However, frailty remains less clearly defined frail with are rarely characterised. The general recommendation guidelines to aim for relaxed glycaemic control, mainly avoid hypoglycaemia, this often-vulnerable group patients. With increasing age development frailty, body composition changes characterised by an increase visceral adipose tissue decrease muscle mass. Depending on the overall weight, differential loss fibre types adipose/muscle ratio, presence any associated can be seen as spectrum metabolic phenotypes that vary insulin resistance which we have two specific phenotypes. sarcopenic obese (SO) phenotype increased fat one side anorexic malnourished (AM) significant reduced other. In view these varying phenotypes, choice hypoglycaemic therapy, targets goals therapy likely different. SO phenotype, weight-limiting agents, especially new agents GLP-1RA SGLT-2 inhibitors, should considered early due their benefits weight reduction ability achieve tight control where focus will cardiovascular risk. AM weight-neutral or limiting further possible anabolic effects insulin. Here, combination avoidance hypoglycaemia; maintenance good quality life. Future research still required develop novel positive effect improvements outcomes.

Язык: Английский

---

GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes

Diabetes & Metabolism, Год журнала: 2023, Номер 49(5), С. 101470 - 101470

Опубликована: Авг. 30, 2023

Glucagon-like peptide 1 (GLP-1) is a hormone of the incretin family, secreted in response to nutrient ingestion, and plays role metabolic homeostasis. GLP-1 receptor agonist has peripheral central action, including stimulation glucose-dependent insulin secretion biosynthesis, inhibition glucagon gastric emptying, food intake. Through their mechanism, use treatment type 2 diabetes been extended management obesity, numerous trials are being conducted assess cardiovascular effect. Type appears share common pathophysiological mechanisms with development cognitive disorders, such as Alzheimer's Parkinson's disease, related resistance. In this review, we aim examine pathological features between dementia, effects, analyze relevant literature about effect analogs on function patients but also without. Results tends show an improvement some brain markers (e.g. hippocampal connections, cerebral glucose metabolism, activation functional magnetic resonance imaging), without able demonstrate strong correlation scores. Some epidemiological studies suggest that agonists may offer protective effect, by delaying progression dementia when diabetic treated agonists. Ongoing progress provide disease-modifying care for disease future.

Язык: Английский

---

Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer’s disease models: a systematic review and meta-analysis of preclinical studies

Frontiers in Pharmacology, Год журнала: 2023, Номер 14

Опубликована: Сен. 13, 2023

Alzheimer's disease (AD) is a degenerative of the nervous system. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), drug used to treat type 2 diabetes, have been shown neuroprotective effects. This systematic review and meta-analysis evaluated effects potential mechanisms GLP-1 RAs in AD animal models. 26 studies were included by searching relevant from seven databases according predefined search strategy inclusion criteria. Methodological quality was assessed using SYRCLE's risk bias tool, statistical analysis performed ReviewManger 5.3. The results showed that, terms behavioral tests, could improve learning memory abilities rodents; pathology, reduce Aβ deposition phosphorylated tau levels brains rodents. therapeutic involves range that work synergistically enhance alleviation various pathological manifestations associated with condition. A total five clinical trials retrieved ClinicalTrials.gov. More large-scale high-quality preclinical should be conducted more accurately assess on AD.

Язык: Английский

---